Poland· PL-100539459
Jascayd
A nerandomilast product containing nerandomilast, registered in Poland by Boehringer Ingelheim International GmbH. The same ATC class is registered in 9 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Nerandomilast is registered in 9 of 19 countries.
Countries holding a registration under ATC L04AA61 (nerandomilast), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 5 of them publish a price we can compare per daily dose
Nerandomilast · ATC L04AA61
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Ireland
- Japan
- Netherlands
- Polandprice
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Nerandomilast
- Manufacturer
- Boehringer Ingelheim International GmbH
- Country
- Poland (PL)
- ATC code
- L04AA61
- ATC class
- Nerandomilast
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 5
- gtin05909991603779
- gtin05909991603762
- gtin05909991603786
- gtin05909991603793
- gtin05909991603809
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Nerandomilast in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaJASCAYDBoehringer Ingelheim International GmbH, Ingelheim am Rhein
- United StatesJASCAYDBoehringer Ingelheim Pharmaceuticals, Inc.
- FinlandJascaydBoehringer Ingelheim International GmbH
- BelgiumJascayd 18 mgBoehringer Ingelheim International
- NetherlandsJascayd 18 mg filmomhulde tablettenBoehringer Ingelheim International GmbH
- SwedenJascayd 18 mg Filmdragerad tablettBoehringer Ingelheim International GmbH
- IrelandJascayd 18 mg film-coated tabletsBoehringer Ingelheim International GmbH
- SpainJASCAYD 18 MG COMPRIMIDOS RECUBIERTOS CON PELICULABoehringer Ingelheim International Gmbh
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Jascayd
- Liechtenstein · Jascayd
- Norway · Jascayd
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/fa592406-1bac-4c66-bc12-d62796369756 GET /v1/drugs/fa592406-1bac-4c66-bc12-d62796369756?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletka powlekana",
"source": "urpl",
"strength": "18 mg",
"packaging": "05909991603762 ¦ Rpz ¦ EU/1/26/2040/006 ¦ 167432\n10 tabl.\n05909991603779 ¦ Rpz ¦ EU/1/26/2040/007 ¦ 167433\n30 tabl.\n05909991603786 ¦ Rpz ¦ EU/1/26/2040/008 ¦ 167434\n60 tabl.\n05909991603793 ¦ Rpz ¦ EU/1/26/2040/009 ¦ 167435\n60 tabl.\n05909991603809 ¦ Rpz ¦ EU/1/26/2040/010 ¦ 167436\n180 tabl.",
"substance": "Nerandomilast/18 mg",
"common_name": "Nerandomilast",
"pl_product_id": "100539459",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about nerandomilast.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.